The number of ongoing research programs continues to increase year after year. Chiesi USA is predominantly focused on the key areas of respiratory, neonatology, and special care.
The respiratory area is the hub of Research & Development activities. These R&D activities are constantly expanding to address areas of therapeutic need in asthma, chronic obstructive pulmonary disease, and other respiratory diseases.
Chiesi USA’s development pipeline consists of new molecular entities and continues to make significant progress. Programs include innovative anti-inflammatory, bronchodilator, and antifibrotic molecules.
Research and Development programs in this therapeutic area are focused devastating respiratory diseases and conditions of the newborn. New programs have progressed and have been added as candidates for the treatment of these other neonatal conditions.
Research and Development in the area of Special Care is focused on cardiovascular conditions. The anti-thrombotic candidate CUSA 081 is now in an advanced stage of development.